)
Visual
test
Niagen Bioscience
Niagen Bioscience (NAGE) investor relations material
Niagen Bioscience 2nd Annual Lytham Partners Healthcare Investor Summit summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.2nd Annual Lytham Partners Healthcare Investor Summit summary15 Jan, 2026
Company overview and product focus
Niagen Bioscience, formerly ChromaDex, specializes in nicotinamide riboside (NR), branded as Niagen, a leading NAD precursor with over 100 patents and extensive clinical validation.
NAD is vital for cellular energy and repair; elevating NAD with Niagen supports resilience against aging and stress-related conditions.
Niagen is offered as a dietary supplement, B2B ingredient, and now as IV/injection, with both food-grade and pharmaceutical-grade options.
The company is net income and cash flow positive, with no debt and a strong, diversified business model.
Tru Niagen is a top-selling supplement in the U.S. and internationally, with growing injectable and IV offerings.
Scientific research and competitive differentiation
Over 41 clinical and 100 preclinical studies published on Niagen, with unmatched R&D investment in the NAD supplement space.
Niagen elevates NAD more efficiently and safely than NAD or NMN supplements, with a natural cellular uptake pathway.
The ChromaDex External Research Program (CERP) has over 300 collaborations with leading institutions, generating significant IP.
The company’s science-driven approach is supported by a network of top global researchers and ongoing patent development.
Business expansion and future plans
Niagen Plus B2B business supplies compound pharmacies for IV/injection products, with a direct-to-consumer telehealth launch planned within six months.
Plans to offer home injection kits and partner with telehealth companies selling similar products, targeting the growing self-injection trend.
Pharmaceutical applications are being pursued, focusing on orphan diseases like Ataxia-telangiectasia, with promising early clinical results.
Skincare is identified as a major future vertical, with aggressive expansion and announcements expected in 2026.
Niagen Plus: future growth and D2C strategy
Detail the orphan disease drug development strategy.
Skincare market opportunity and 2026 strategy.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- XEL
Ongoing EPS reached $3.80 in 2025; 2026 guidance is $4.04–$4.16 with a $60B capital plan. - EL
Strong Q2 results and raised FY26 outlook, with sales and margins up despite headwinds. - KCR
Record profitability and strong orders in 2025; stable outlook for 2026 amid uncertainties. - 532539
Record Q3 FY26 revenue and profit growth, major expansions, and strong industry outlook. - HAE
Gross margin and net income rose despite lower revenue; guidance for EPS and cash flow increased. - QIGD
Revenue up 18% but net profit down 15% as higher costs and dividends reduced margins and equity. - MYCR
Record annual sales, Q4 order drop, strong Global Technologies, and four acquisitions. - 532548
Revenue up 18.4% YoY, margin gains, and capacity expansions support a positive outlook. - THERMAX
Profit after tax rose 80% and order booking grew 34%, led by Infra and data center wins. - LPG
Net income more than doubled on strong TCE rates, higher revenues, and efficient fleet operations.
Next Niagen Bioscience earnings date
Q4 20255 Mar, 2026
Niagen Bioscience
Next Niagen Bioscience earnings date
Q4 20255 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
ChromaDex Corporation is a biosciences company that develops and markets ingredients and consumer products based on nicotinamide riboside and other proprietary compounds. Its product portfolio supports healthy aging and cellular health, distributed through e-commerce and retail. The company is headquartered in Los Angeles, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage